144 related articles for article (PubMed ID: 37475819)
21. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.
Zhou H; Wang XJ; Jiang X; Qian Z; Chen T; Hu Y; Chen ZH; Gao Y; Wang R; Ye WW; Cao WM
Breast Cancer Res Treat; 2019 Nov; 178(1):63-73. PubMed ID: 31364001
[TBL] [Abstract][Full Text] [Related]
22. The role of TPS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer.
Zhang J; Wei Q; Dong D; Ren L
Clin Chim Acta; 2021 Dec; 523():19-25. PubMed ID: 34454906
[TBL] [Abstract][Full Text] [Related]
23. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
24. Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer.
Gaspar MJ; Diez M; Rodriguez A; Ratia T; Martin Duce A; Galvan M; Granell J; Coca C
Anticancer Res; 2003; 23(4):3427-32. PubMed ID: 12926084
[TBL] [Abstract][Full Text] [Related]
25. Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer.
Yonemori K; Katsumata N; Noda A; Uno H; Yunokawa M; Nakano E; Kouno T; Shimizu C; Ando M; Tamura K; Takeuchi M; Fujiwara Y
J Cancer Res Clin Oncol; 2008 Nov; 134(11):1199-206. PubMed ID: 18528707
[TBL] [Abstract][Full Text] [Related]
26. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
Safi F; Kohler I; Röttinger E; Beger H
Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
[TBL] [Abstract][Full Text] [Related]
27. Serum CA724 has no diagnostic value for gastrointestinal tumors.
Cao H; Zhu L; Li L; Wang W; Niu X
Clin Exp Med; 2023 Oct; 23(6):2433-2442. PubMed ID: 36920593
[TBL] [Abstract][Full Text] [Related]
28. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.
Bartlett JM; Thomas J; Ross DT; Seitz RS; Ring BZ; Beck RA; Pedersen HC; Munro A; Kunkler IH; Campbell FM; Jack W; Kerr GR; Johnstone L; Cameron DA; Chetty U
Breast Cancer Res; 2010; 12(4):R47. PubMed ID: 20615243
[TBL] [Abstract][Full Text] [Related]
29. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery.
Nakamura T; Kimura T; Umehara Y; Suzuki K; Okamoto K; Okumura T; Morizumi S; Kawabata T
Surg Today; 2005; 35(1):19-21. PubMed ID: 15622458
[TBL] [Abstract][Full Text] [Related]
30. Combined evaluation of postoperative serum levels of carcinoembryonic antigen less than or equal to 2.5 ng/ml and absence of vascular invasion may predict no recurrence of stage I adenocarcinoma lung cancer.
Kashiwabara K; Saeki S; Sasaki J; Nomura M; Kohrogi H
J Thorac Oncol; 2008 Dec; 3(12):1416-20. PubMed ID: 19057266
[TBL] [Abstract][Full Text] [Related]
31. Identifying patients at risk of early postoperative recurrence of lung cancer: a new use of the old CEA test.
Buccheri G; Ferrigno D
Ann Thorac Surg; 2003 Mar; 75(3):973-80. PubMed ID: 12645726
[TBL] [Abstract][Full Text] [Related]
32. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse.
Sugano K; Ushiama M; Fukutomi T; Tsuda H; Kitoh T; Ohkura H
Int J Cancer; 2000 Jul; 89(4):329-36. PubMed ID: 10956406
[TBL] [Abstract][Full Text] [Related]
33. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.
Park BJ; Cha MK; Kim IH
BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391
[TBL] [Abstract][Full Text] [Related]
34. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
[TBL] [Abstract][Full Text] [Related]
35. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
36. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
Zheng H; Luo RC
Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
[TBL] [Abstract][Full Text] [Related]
37. Does serum CA19-9 play a practical role in the management of patients with colorectal cancer?
Morita S; Nomura T; Fukushima Y; Morimoto T; Hiraoka N; Shibata N
Dis Colon Rectum; 2004 Feb; 47(2):227-32. PubMed ID: 15043294
[TBL] [Abstract][Full Text] [Related]
38. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer.
He CZ; Zhang KH; Li Q; Liu XH; Hong Y; Lv NH
BMC Gastroenterol; 2013 May; 13():87. PubMed ID: 23672279
[TBL] [Abstract][Full Text] [Related]
39. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
[TBL] [Abstract][Full Text] [Related]
40. CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer.
Svobodova S; Kucera R; Fiala O; Karlikova M; Narsanska A; Zedníková I; Treska V; Slouka D; Rousarova M; Topolcan O; Finek J
Anticancer Res; 2018 Jan; 38(1):465-469. PubMed ID: 29277810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
